48 results about "Fovea centralis" patented technology

ABSTRACT OF THE DISCLOSURE The newly discovered retinal ganglion cell photoreceptor melanopsin absent in the central fovea of the eye but distributed throughout the remaining human retinal body provides both non-visual biological / physiological input inducing circadian entrainment, and visual input affecting perceived brightness; this perceived brightness is not the object brightness commonly associated with luminance and perceived color of an object in central view, but the perception of brightness of a whole space or task background. Discussed are improvements to circadian lighting systems based on melanopsin stimulation whereby ambient and / or device background lighting may be temporally tuned over a range of prescribed color temperatures from a first subset of lighting having a higher melanopic content to a second subset of lighting having a lower melanopic content or vice versa in accordance with a desired circadian cycle, and in a manner where net light output is of a constant perceived brightness and color throughout temporal tuning.

A prism prescription value acquisition system that includes a calculation part for numerically transforming a fixation disparity amount (unit: angle), which indicates a degree at which the visual axis is shifted from the central fovea of the retina when a subject conducts visual fixation of a target, into a prism prescription value by multiplying the fixation disparity amount by a coefficient when the fixation disparity amount is within ±4 minutes. Herein, the prism prescription value is calculated according to the following equation: APver=kver*FDver, APhor=khor*FDhor providing that each of coefficients khor and kver satisfies the following conditions: 0.3≦kver≦0.7, 1.4≦khor≦2.0.

Intraocular injection of adeno-associated viral (AAV) vectors has been an evident route for delivering gene drugs into the retina. Currently, the vectors need to be injected into the subretinal spacein order to provide gene delivery to cones. In this approach, gene delivery is limited to cells that contact the local "bleb" of injected fluid. Furthermore, retinal detachment that occurs during subretinal injections is a concern in eyes with retinal degeneration. Here, the inventors establish several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea with supporting studies in mouse models, human induced pluripotent stem cell-derived organoids, post-mortem human retinal explants and living macaques. They show that an AAV9variant provides efficient foveal cone transduction when injected into the subretinal space several millimeters away from the fovea, without detaching this delicate region. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Accordingly, the present invention relates to method of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein asset forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12.

An intraocular lens system comprising a single lens comprising two optical surfaces selected to maintain image quality at the foveal centre whilst reducing image aberration at preferred retinal locus locations outside of the fovea region.